Background: Soluble urokinase-type plasminogen activator receptor (suPAR) is a circulating protein that has been found to be a promising biomarker for a variety of kidney injuries. The predictive utility of suPAR in contrast-induced acute kidney damage (CI-AKI) in percutaneous coronary intervention (PCI) is uncertain. Aim: This study aimed to assess the prediction of CI-AKI using suPAR in patients undergoing PCI. Methods: This case-control study was carried out on 80 subjects undergoing PCI. The subjects were divided into two groups. Forty patients developed CIAKI, in addition to the control group, which included 40 subjects with non- CI-AKI.The radial or right femoral artery was punctured using the PCI Seldinger puncture technique. A specific laboratory investigation was the evaluation of suPAR in serum using the Luminex assay. Results: The suPAR marker was a significant predictor of CI-AKI among PCI patients (AUC=0.982, P<0.001). The suPAR cutoff point (>2.55 ng/mL) showed a sensitivity of 92.5% and a specificity of 97.5% for the diagnosis of CI-AKI. Combined creatinine before contrast and suPAR cutoff points showed a sensitivity of 95% and a specificity of 100%. In CI-AKI patients, there was a significant positive correlation between suPAR marker levels and each creatinine level after contrast (r=0.375, P=0.017) and urinary albumin creatinine ratio (r=0.396, P=0.011). Increased levels of suPAR were associated with higher odds for having CI-AKI (OR 2334.63). Conclusions: Higher suPAR levels were detected in cases in comparison to controls. SuPAR showed accepted performance criteria in CI-AKI prediction. The combined creatinine level before contrast and suPAR improves the sensitivity and specificity. The suPAR seems to be a predictor of CI-AKI in primary PCI.